Release: Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinson’s Disease

Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson’s disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has successfully completed experiments demonstrating that MANF has an excellent diffusion profile in the striatum of rat brains.

Read more »

Release: Amarantus BioSciences Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parkinson’s Disease

The following is a news release published October 25 by Amarantus BioSciences discussing positive behavioural efficacy data for MANF, the company’s powerful therapeutic protein with neuron-protective properties. Data from a neurorestoration 6-hydroxydopamine (6-OHDA) rat model Parkinson’s disease shows superiority of MANF over GDNF.

Read more »